HEK-Blue™ IL-12 Cells
-
Cat.code:
hkb-il12
- Documents
ABOUT
IL-12 responsive STAT4-SEAP reporter assay
HEK-Blue™ IL-12 cells are designed to monitor interleukin 12 (IL-12)-induced STAT4 stimulation or inhibition. This colorimetric bioassay can be used for screening activatory molecules, such as engineered cytokines, or inhibitory molecules, such as neutralizing antibodies.
HEK-Blue™ IL-12 cells respond specifically to recombinant human IL-12 and mouse IL-12. The reliable and consistent performance of HEK-Blue™ IL-12 cells makes them suitable for release assays of therapeutic molecules that inhibit IL-12 signaling, such as Ustekinumab, a monoclonal antibody targeting the IL-12 p40 subunit (see figures).
Key features
- Readily assessable STAT4-SEAP reporter activity
- Convenient readout using QUANTI-Blue™ Solution
- High sensitivity to human (h) IL-12 and mouse (m) IL-12 activity
- Stability guaranteed for 20 passages
Applications
- Therapeutic development
- Drug screening
- Release assay
Interleukin 12 (IL-12) is a pleiotropic cytokine driving IFN-γ production, proliferation of activated T and NK cells, and differentiation of Th1 cells in response to microbial infections. Dysregulated IL-12 production is associated with immune-mediated inflammatory diseases, including psoriasis, rheumatoid arthritis, Crohn's disease, and multiple sclerosis.
Disclaimer: These cells are for internal research use only and are covered by a Limited Use License (See Terms and Conditions). Additional rights may be available.
InvivoGen also offers
SPECIFICATIONS
Specifications
IL-12
Human, Mouse
Detection and quantification of IL-12 activity
1 ng/ml - 100 ng/ml (hIL-12 and mIL-12)
Complete DMEM (see TDS)
Verified using Plasmotest™
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:HEK-Blue™ IL-12 Cells
-
Cat code:hkb-il12
-
Quantity:3-7 x 10^6 cells
- 2 x 1 ml HEK-Blue™ Selection (250x concentrate)
- 1 ml Normocin® (50 mg/ml)
- 1 ml of QB reagent and 1 ml of QB buffer (sufficient to prepare 100 ml of QUANTI-Blue™ Solution, a SEAP detection reagent)
Shipping & Storage
- Shipping method: Dry ice
- Liquid nitrogen vapor
- Upon receipt, store immediately in liquid nitrogen vapor. Do not store cell vials at -80°C.
Storage:
Caution:
Details
Cell line description
HEK-Blue™ IL-12 cells were generated by stable transfection with the genes encoding for the human IL-12 receptor (IL-12Rβ1 and IL-12Rβ2 chains), JAK2, and a STAT4-inducible secreted embryonic alkaline phosphatase (SEAP) reporter. The binding of IL-12 to its receptor triggers a signaling cascade leading to the activation of STAT4 and the subsequent production of SEAP. This can be readily assessed in the supernatant using QUANTI-Blue™ Solution, a SEAP detection reagent.
HEK-Blue™ IL-12 cells detect human (h) and mouse (m) IL-12. These cells also respond, to a weaker extent, to hIL-27 and hIFN-β. However, they do not respond to other STAT4-signaling cytokines of the IL-12 cytokine receptor family: IL-23 and IL-35 (see figures).
IL-12 background
Interleukin 12 (IL-12), also known as IL-12p70, cytotoxic lymphocyte maturation factor (CLMF), or natural killer cell stimulatory factor (NKSF) is the founding member of the heterodimeric IL-12 cytokine family. This family is characterized by the sharing of p19, p28, p35, p40, and Ebi3 subunits, and includes IL-12, IL-23, IL-27, IL-35, and IL-39 [1, 2]. The secretion of bioactive IL-12 requires the co-expression of IL-12p35 and IL-12p40 and disulfide bond formation. IL-12 is primarily produced by pathogen-activated macrophages and dendritic cells (DC) [1, 2].
The binding of IL-12 to its IL-12Rβ1/IL-12Rβ2 heterodimeric receptor triggers a JAK2/TYK2 signal transduction leading to the activation of STAT4. Activated STAT4 forms homodimers that are translocated to the nucleus where they regulate the expression of target genes. Subsequent gene expression promotes the cytotoxic activity of Natural Killer (NK) and CD8+ T cells, and drives IFN-γ production by NK and activated CD4+ T cells [1, 2]. IFN-γ contributes to the differentiation of Th1 cells and inhibits Th2 cell development. Moreover, it enhances DC maturation and antigen presentation.
Interestingly, secreted IL-12p40 monomers and homodimers (IL-12p80) have also been found and described to function as IL-12 antagonists or agonists, depending on the experimental studies [2].
Relevance for therapeutics development
IL-12 is a key cytokine for controlling intracellular infections. However, excessive IL-12 production contributes to several immune-mediated inflammation diseases including rheumatoid arthritis, type I diabetes, multiple sclerosis, and Crohn's disease [1].
Ustekinumab is a fully human monoclonal antibody (mAb) that targets the p40 subunit common to IL-12 and IL-23, preventing their interactions with their receptor common chain IL-12Rβ1 [3]. This antibody is FDA-approved for treating psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis [4]. Addressing the benefits of neutralizing IL-12 and IL-23 together or individually, depending on the clinical context can be achieved using neutralizing mAbs targeting the p19 subunit of IL-23 [5].
As IL-12 drives strong pro-inflammatory and cytotoxic activities, a series of IL-12-based products have been explored for cancer therapy. These strategies must control targeted delivery to achieve high local IL-12 while avoiding systemic toxicity [6-8].
References:
1. Dembic., Z., 2015. Chapter 6 - Cytokines of the immune system: Interleukins. The cytokines of the immune system (book): 143-239.
2. Floss, D.M., et al., 2020. IL-12 and IL-23-Close Relatives with Structural Homologies but Distinct Immunological Functions. Cells, 9(10): 2184.
3. Benson, J.M, et al., 2011. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 3(6):535-545.
4. FDA website accessed in Nov 2024: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761044s013lbl.pdf#page=37
5. Tait Wojno, E.D. et al., 2019. The Immunobiology of the Interleukin-12 Family: Room for Discovery. Immunity. 50(4):851-870.
6. Leonard, W.J. & Lin, J. X., 2023. Strategies to therapeutically modulate cytokine action. Nat Rev Drug Discov. 22(10):827-584.
7. Briukhovetska D., et al., 2021. Interleukins in cancer: from biology to therapy. Nat Rev Cancer. 21(8):481-499.
8. Yi, M., et al., 2024. Targeting cytokine and chemokine signaling pâthways for cancer therapy. Signal Transduction and Targeted Therapy. 9(1):176.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
FAQ
HEK293 cell line description
The only HEK-Blue™ Null cells that are sensitive to Puromycin are the HEK-Blue™ Null1-v cells.
Our RNAseq data confirms that our HEK-Blue™ cells express FcRN, however, this has not been functionally tested.
The difference in activity is approximately 10-fold.
Both cell types overexpress a designated TLR. The primary difference is that HEK-Blue™ cells include the NFκB inducible SEAP reporter construct.
We presume them to be in the endosome as we express the wild-type, full-length genes. Additionally, their signal can be blocked by Chloroquine, an endosomal acidification inhibitor. However, as these TLRs are over-expressed there may potentially be low expression of them on the cell surface.
HEK-Blue™ cells only express a single NFκB inducible SEAP reporter gene. Whereas, HEK-Dual™ cells have the addition of the Lucia™ gene knocked into the IL-8 locus. Thus, when IL-8 is activated following stimulation, HEK-Dual™ cells can report this with the secretion of Lucia™ luciferase.
It should also be noted that the HEK-Dual™ cells have been knocked out for TLR3, TLR5, and TNFR to limit interference from other TLRs when studying a specific TLR pathway.
HEK293 cells express TLR1, TLR3, TLR5, TLR6, and NOD1.
They respond to TLR3, TLR5, and NOD1 agonists, but at a much lower level compared to HEK293 cells transfected with these receptors
HEK-Blue™ IL-1R cells express both human and murine IL-1β receptors, thus can detect both species.
On the other hand, HEK-Blue™ IL-1β cells are specific for human IL-1β, but can still detect higher concentrations of mouse IL-1β.
In the United States, HEK293 cell lines are designated Biosafety Level 2 according to the Center for Disease Control and Prevention (CDC).
In Germany, HEK293 cell lines are designated Biosafety Level 1 according to the Central Committee of Biological Safety, Zentrale Kommission für die Biologische Sicherheit (ZKBS).
You can check with your country’s regulatory authority regarding the use of these cells.
Please note that there is no replicating/infectious Adenovirus 5 in these cells.
The minimal promoter isn't the same but the difference in expression for these two Null cell lines is minor.
There is no specific integration system used to generate our stable cell lines.
The selection pressure is enough to obtain stable clones. The receptors are added by simple transfection of plasmids using a cationic lipidic transfection agent (the plasmids are not linearized before transfection).
Only our HEK-Blue™ Null1-k and Null2-k cells are sensitive to G418.
The only HEK-Blue™ Null cells that are sensitive to Puromycin are the HEK-Blue™ Null1-v cells.
Cell line culture
Trypsin does not adversely affect the health or growth of these cells. However, it is known that high concentrations will occasionally induce the activation of NFκB resulting in a higher background in your assay.
Moreover, we have observed some cases where trypsin has been contaminated with TLR2, TLR4, and TLR5 contaminants, which can also interfere with the assay results.
It is not unusual for different TLR cells to grow at different rates. Some TLR clones happen to grow a little slower/faster than others. This is often clone dependent.
When the HEK-Blue™ cells are non-adherent, either they were diluted too harshly at the start or they have grown over-confluent in a small flask and suffocated.
To avoid this in the future:
• Change the media and plate the cells at a density of approximately 1.5 x 106 cells in a T25 flask.
• Wash the cells before putting them into a new flask. Sometimes when the cells are non-adherent, it is due to the clustering of both live and dead cells. Additionally, this will get rid of any remaining DMSO which could affect the adhesion of the cells to the flask.
• Use medium with 20% FBS.
• The use of CellBIND flasks can sometimes help to increase attachment and growth of the cells (however CellBIND flasks are not required in the normal protocol).
The split ratio will depend on when you expect confluency. Typically, the doubling time of HEK-Blue™ cells is approximately 24 hours.
Therefore, if you use a split ratio of 1:2 (50%) into a new flask, cells should be confluent the following day. If you use a split ratio of 1:4 (25%) you can expect the cells to be confluent after 2 days.
Our HEK-Blue™ Selection is provided in 1ml tubes with each containing a 250X solution.
Therefore, you should dilute HEK-Blue™ Selection 1:250 into your media to have a 1X concentration.
HEK-Blue™ cells should be seeded at a density of approximately 1.5 x 106 cells in a T25 flask or 4 – 5 x 106 cells in a T75 flask.
We recommend using a flat-bottom, clear walled cell culture plate.
Below are a few tips we recommend to help get your HEK cells growing:
• For the first 2-3 passages, grow cells in media containing 20% FBS and no antibiotics.
• Do not allow cells to reach 100% confluency Please check cells as regularly as possible.
• The cells should not be grown in 20% FBS for too long. Use media with 10% FBS after 2 or 3 passages.
• When making frozen stocks, continue growing additional cultures in case there is a problem with the frozen stock.
Assays
There are 2 possible explanations as to why a blue color is observed in all wells.
1. It could be due to the presence of Alkaline Phosphatase (AP) in the culture medium. To see if this is the case, there is a very simple test to perform. Add 50 µl of the medium used for cell culture (without cells) and 200 µl of resuspended HEK-Blue™ detection medium or QUANTI-Blue™. If the medium turns blue, then it is due to the presence of Alkaline Phosphatase (AP) in the serum of the media. In this case, you must heat the serum to inactivate the AP and repeat the medium test. At this point the test should give a negative result (no blue color).
2. It could be due to improper handling of cells before the test. To avoid activation of NFκB before stimulation and reduce the risk of false positive results:
• Use pre-warmed PBS to wash cells
• Use heat-inactivated FBS
• Do not centrifuge cells prior to stimulation
• Do not use trypsin
We have noticed a loss of sensitivity when using HEK-Blue™ Detection medium instead of QUANTI-Blue™ on our cytokine reporter cell lines.
Therefore, we recommend using QUANTI-Blue™, which is provided with the cells, as this is what we use in house.
We recommend to not use any antibiotics at all during assays to ensure the least amount of potential interfering agents in the medium.
Therefore, we do not add HEK-Blue™ Selection to the test media.
We have only tested the use of plasma and serum samples on our HEK-Blue™ hTLR2 cell line.
The results demonstrated that when compared to using standard samples (in DMEM), serum samples give a single log difference.
On the other hand, we found a 3-log difference between DMEM and plasma samples.
This is why we would recommend using serum samples over plasma samples.
Yes, they can be used interchangeably. However, please note that the protocols are distinctly different and need to be followed accordingly.
HEK293 cells are very easy to transfect with a transfection efficiency of approximately 80%.
It depends on the cell line and the concentration of the ligand used to stimulate the cells. In general, we record the results following 16 – 24 hours of stimulation.